logo
No Surprises In Skyworks Solutions's (NASDAQ:SWKS) Q4 Sales Numbers, Provides Optimistic Revenue Guidance for Next Quarter

No Surprises In Skyworks Solutions's (NASDAQ:SWKS) Q4 Sales Numbers, Provides Optimistic Revenue Guidance for Next Quarter

Yahoo05-02-2025

Wireless chips maker Skyworks Solutions (NASDAQ: SWKS) met Wall Street's revenue expectations in Q4 CY2024, but sales fell by 11.1% year on year to $1.07 billion. The company expects next quarter's revenue to be around $950 billion, coming in 100,716% above analysts' estimates. Its non-GAAP profit of $1.60 per share was 1.7% above analysts' consensus estimates.
Is now the time to buy Skyworks Solutions? Find out in our full research report.
Revenue: $1.07 billion vs analyst estimates of $1.07 billion (11.1% year-on-year decline, in line)
Adjusted EPS: $1.60 vs analyst estimates of $1.57 (1.7% beat)
Adjusted Operating Income: $284.8 million vs analyst estimates of $283.4 million (26.7% margin, in line)
Revenue Guidance for Q1 CY2025 is $950 billion at the midpoint, above analyst estimates of $942.3 million
Adjusted EPS guidance for Q1 CY2025 is $1.20 at the midpoint, above analyst estimates of $1.19
Operating Margin: 16.9%, down from 21.5% in the same quarter last year
Free Cash Flow Margin: 31.7%, down from 62.6% in the same quarter last year
Inventory Days Outstanding: 102, down from 120 in the previous quarter
Market Capitalization: $13.81 billion
'Skyworks started the new fiscal year with solid results, growing revenue 4% sequentially and surpassing the midpoint of our guidance,' said Liam K. Griffin, chief executive officer and president of Skyworks.
Result of a merger of Alpha Industries and the wireless communications division of Conexant, Skyworks Solutions (NASDAQ: SWKS) is a designer and manufacturer of chips used in smartphones, autos, and industrial applications to amplify, filter, and process wireless signals.
Demand for analog chips is generally linked to the overall level of economic growth, as analog chips serve as the building blocks of most electronic goods and equipment. Unlike digital chip designers, analog chip makers tend to produce the majority of their own chips, as analog chip production does not require expensive leading edge nodes. Less dependent on major secular growth drivers, analog product cycles are much longer, often 5-7 years.
Examining a company's long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Unfortunately, Skyworks Solutions's 4.1% annualized revenue growth over the last five years was sluggish. This fell short of our benchmark for the semiconductor sector and is a tough starting point for our analysis. Semiconductors are a cyclical industry, and long-term investors should be prepared for periods of high growth followed by periods of revenue contractions.
Long-term growth is the most important, but short-term results matter for semiconductors because the rapid pace of technological innovation (Moore's Law) could make yesterday's hit product obsolete today. Skyworks Solutions's history shows it grew in the past but relinquished its gains over the last two years, as its revenue fell by 12.7% annually.
This quarter, Skyworks Solutions reported a rather uninspiring 11.1% year-on-year revenue decline to $1.07 billion of revenue, in line with Wall Street's estimates. Company management is currently guiding for a 90,722% year-on-year increase in sales next quarter.
Looking further ahead, sell-side analysts expect revenue to remain flat over the next 12 months. Although this projection implies its newer products and services will catalyze better top-line performance, it is still below average for the sector.
Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Days Inventory Outstanding (DIO) is an important metric for chipmakers, as it reflects a business' capital intensity and the cyclical nature of semiconductor supply and demand. In a tight supply environment, inventories tend to be stable, allowing chipmakers to exert pricing power. Steadily increasing DIO can be a warning sign that demand is weak, and if inventories continue to rise, the company may have to downsize production.
This quarter, Skyworks Solutions's DIO came in at 102, which is 34 days below its five-year average. At the moment, these numbers show no indication of an excessive inventory buildup.
Despite in line revenue, we liked seeing Skyworks Solutions's strong improvement in inventory levels. We were also glad its revenue guidance for next quarter came in much higher than Wall Street's estimates. Overall, we think this was still a solid quarter with some key areas of upside. The stock remained flat at $87.50 immediately after reporting.
Skyworks Solutions may have had a good quarter, but does that mean you should invest right now? When making that decision, it's important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here, it's free.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The S&P 500 is taking a $9.8 trillion roundtrip. Here's what's going on
The S&P 500 is taking a $9.8 trillion roundtrip. Here's what's going on

Yahoo

time17 minutes ago

  • Yahoo

The S&P 500 is taking a $9.8 trillion roundtrip. Here's what's going on

The S&P 500 on Thursday flirted with closing at an all-time high, vying to complete a whirlwind roundtrip that saw the benchmark US stock index shed and then regain $9.8 trillion in market value across just four months. The S&P 500 has been on a roller coaster ride this year as President Donald Trump's trade policy has jolted markets. The S&P 500 hit its last record high on February 19 before dropping as low as 18.9% by early April as tariff confusion rocked markets. The index has soared more than 23% since hitting its low point on April 8, in what has been a remarkable come back from the precipice of a bear market. US stocks were higher on Thursday. The Dow was higher by 399 points, or 0.93%. The broader S&P 500 gained 0.83% and the tech-heavy Nasdaq Composite rose 1.02%. The S&P 500 needs to finish the day with a gain of 0.86% or more to notch a record high. The Nasdaq on Thursday was also vying to close at an all-time high and surpass its previous record set on December 16. The tech-heavy index dropped into a bear market in early April before surging into a new bull market and gaining 32%. Stocks pushed higher on Thursday morning amid a flurry of economic data, including data that showed a downward revision to how much the economy contracted in the first quarter. That revised data is 'backward looking,' and markets were higher on Thursday because they have already priced in the turmoil from earlier this year, Paul Stanley, chief investment officer at Granite Bay Wealth Management, said in an email. 'The market is betting on continued progress on trade and a de-escalation of tensions in the Middle East is giving investors confidence,' Stanley said. While the S&P 500 and Nasdaq have recovered, the Dow is still 3.9% away from its record high set in December. The Dow this year has been weighed down by stocks like UnitedHealth Group (UNH), which is down 40%. At its low on April 8, the S&P 500 had shed $9.8 trillion in market value since its record high on February 19, according to FactSet data. The index is set to recover all of that market value as it tests a new record high. Wall Street analysts are mixed on whether the S&P 500 can grind higher, or whether its return to record highs means there's more downside to come. As tensions in the Middle East have settled, the focus returns to Trump's agenda. Lawmakers hope to deliver the president's budget bill to his desk by July 4, and his administration's deadline for trade deals is July 9. 'Meaningful progress on any of the two matters can bolster equities to fresh records,' José Torres, senior economist at Interactive Brokers, said in a note. Investors in coming weeks will be focused on how tariff rates ultimately settle and whether Trump's trade policy might reignite inflation. 'It would help stocks if we were to see a narrative shift from a focus on tariff, trade policy and geopolitics to company fundamentals,' Carol Schleif, chief market strategist, BMO Private Wealth, said in a note. Despite the rally, the ratio of bullish versus bearish outlooks for the market remains below the historical average, Ed Yardeni, president of Yardeni Research, said in a note. 'That suggests more upside for the stock market since many investors remain wary and are not overly bullish,' Yardeni said. 'Greed' was the sentiment driving the market on Thursday, according to CNN's Fear and Greed index. It was the highest reading on the index in two weeks. The US dollar on Thursday dropped to its lowest level since February 2022 after a report by the Wall Street Journal that Trump plans to announce his pick for Federal Reserve Chair Jerome Powell's successor as early as this fall. Powell's term ends in May 2026, meaning there would effectively be a 'shadow' Fed chair in the months before his term expires. The US dollar index, which measures the dollar's strength against six major foreign currencies, was down 0.57% as of the afternoon. 'A candidate who is perceived as being more open to lowering rates in line with President Trump's demands would reinforce the US dollar's current weakening trend,' Lee Hardman, senior currency analyst at MUFG, said in a note. The dollar index has tumbled nearly 10% this year. The euro and British pound this year have both hit their highest levels against the dollar in four years. Francesco Pesole, an FX strategist at ING, told CNN that concerns about the Fed's independence have been one of the contributing factors to the dollar's broad decline this year. 'One of the key foundations of the strong dollar, of the dollar as a dominant currency globally, is to have an independent central bank,' Pesole said. 'So, if [global investors] feel there is greater influence of politics into the Fed's decisions, then they are pricing in a greater risk for the dollar.' Greg Valliere, chief US policy strategist at AGF Investments, said in a note that Trump announcing Powell's successor is a 'terrible idea,' as it would be 'sure to annoy and confuse the financial markets if there are two Fed chairs.' 'The damage to the Fed's independence would be considerable if Trump becomes a monetary back-seat driver, second-guessing Fed policies this fall,' Valliere said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy
Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy

Yahoo

time35 minutes ago

  • Yahoo

Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy

Monopar Therapeutics Inc. (NASDAQ:MNPR) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 23, Chardan analyst Keay Nakae began coverage of the company's stock with a 'Buy' rating and a price objective of $60, as reported by The Fly. The firm cited potential in its late-stage Wilson disease treatment as well as an early-stage radiopharmaceutical pipeline for the rating. In the research note, the analyst mentioned that the company's co-founder and Chief Executive Officer has a long history with the development of ALXN1840. Close-up of a scientist using a microscope to study a sample, as part of a research project related to cancer prevention. On May 7, 2025, Monopar Therapeutics Inc. (NASDAQ:MNPR) presented long-term efficacy and safety data for ALXN1840 (tiomolybdate choline). The data supported ALXN1840 as a potential treatment for Wilson disease. Pooled results from 3 clinical trials (n=255) exhibited sustained clinical benefits over a median treatment duration of 2.63 years. Monopar Therapeutics Inc. (NASDAQ:MNPR), in collaboration with Excel Diagnostics and Nuclear Oncology Center (EDNOC), announced that the physician-sponsored Expanded Access Program (EAP) for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu has received authorization to proceed from the US FDA. While we acknowledge the potential of MNPR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MNPR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None.

Stephens Upgrades Exelixis (EXEL) Stock, Raises PT
Stephens Upgrades Exelixis (EXEL) Stock, Raises PT

Yahoo

time35 minutes ago

  • Yahoo

Stephens Upgrades Exelixis (EXEL) Stock, Raises PT

Exelixis, Inc. (NASDAQ:EXEL) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 24, Stephens upgraded the company's stock to 'Overweight' from 'Equal Weight' with a price objective of $60, an increase from the prior target of $29, as reported by The Fly. As per the analyst, the firm has a better understanding of how CABOMETYX will be able to retain market share in RCC, amidst competition and triplet combination trials in progress. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. This gives confidence regarding the franchise to retain its market share in RCC and add growth from NET. Furthermore, the firm highlighted that there is an increased probability of success for zanzalintinib getting FDA approval and market opportunity. In Q1 2025, Exelixis, Inc. (NASDAQ:EXEL) delivered strong financial performance thanks to the accelerating growth in CABOMETYX demand, new patient starts, and revenues. In March, Exelixis, Inc. (NASDAQ:EXEL) announced that the US FDA approved CABOMETYX for the treatment of adult and pediatric patients who are aged 12 years and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic NET (pNET), and adult and pediatric patients aged 12 years and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET (epNET). Riverwater Partners, an investment management company, released its Q4 2024 investor letter. Here is what the firm said: 'Exelixis, Inc. (NASDAQ:EXEL) is a commercial-stage oncology company focused on developing therapies for cancer; its blockbuster commercial asset, Cabozantinib, derived ~$2B in global revenues in 2023 and 2024. The company also has a compelling early-stage pipeline. EXEL is not in the business of me-too programs and trying to get FDA results that are just good enough; FDA approval is the starting line, not the finish line. EXEL manages its portfolio of current and prospective drug candidates to drive innovation to improve the standard of care for patients, having found that generating differentiated data that moves the standard of care is what drives value for patients and EXEL over the long-term. The stock trades at a below-the-market multiple and a 25% discount to its five-year average forward valuation.' While we acknowledge the potential of EXEL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than EXEL and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store